A5034957734- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Protein Kinase Regulation and GTPase Signaling
- Metabolism, Diabetes, and Cancer
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- PI3K/AKT/mTOR signaling in cancer
- Genetics and Physical Performance
- Cystic Fibrosis Research Advances
- Eosinophilic Disorders and Syndromes
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- RNA regulation and disease
- RNA Research and Splicing
- Nonmelanoma Skin Cancer Studies
- Inflammatory Biomarkers in Disease Prognosis
- 3D Printing in Biomedical Research
- Cellular Mechanics and Interactions
- Cell death mechanisms and regulation
- Muscle Physiology and Disorders
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Melanoma and MAPK Pathways
Istituto Oncologico Veneto
2022-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2024-2025
University of Padua
2013-2019
National Research Council
2019
Neuroscience Institute
2019
To evaluate cytokine and soluble programmed death ligand-1 (sPD-L1) levels in the serum plasma of cancer patients treated with immunotherapy, to test different assays.
Abstract Background Immune Checkpoint Inhibitors (ICIs) lead to durable response and a significant increase in long-term survival patients with advanced malignant melanoma (MM) Non-Small Cell Lung Cancer (NSCLC). The identification of serum cytokines that can predict their activity efficacy, sex interaction, could improve treatment personalization. Methods In this prospective study, we enrolled immunotherapy-naïve affected by MM NSCLC treated ICIs. primary endpoint was dissect the potential...
Chronic myeloid leukaemia (CML) is driven by the fusion protein Bcr‐Abl, a constitutively active tyrosine kinase playing crucial role in initiation and maintenance of CML phenotype. Despite great efficacy Bcr‐Abl‐specific inhibitor imatinib, resistance to this drug recognized as major problem treatment. We found that LAMA84 cells, characterized imatinib‐resistance caused BCR‐ABL1 gene amplification, pro‐survival CK2 up‐regulated compared sensitive cells. exhibits higher protein‐level...
Insulin plays a major role in glucose metabolism and insulin-signaling defects are present obesity diabetes. CK2 is pleiotropic protein kinase implicated fundamental cellular pathways abnormally elevated tumors. Here we report that human murine adipocytes CK2-inhibition decreases the insulin-induced glucose-uptake by counteracting Akt-signaling GLUT4-translocation to plasma membrane. In mice acts on adipose tissue, liver skeletal muscle its acute inhibition impairs tolerance. Notably,...
Circulating melanoma cells (CMCs) are responsible for the hematogenous spread of and, ultimately, metastasis. However, their study has been limited by low abundance in patient blood and heterogeneous expression surface markers. The FDA-approved CellSearch platform enriches CD146-positive CMCs, whose number correlates with progression-free survival overall survival. a single marker may not be sufficient to identify them all. Parsortix system allows enrichment CMCs based on size deformability,...
Casein kinase 2 (CK2) is a tetrameric protein composed of catalytic (α and α′) regulatory β subunits. Our study provides the first molecular cellular characterization different CK2 subunits, highlighting their individual roles in skeletal muscle specification differentiation. Analysis C2C12 cell knockout for each subunit reveals that: 1) CK2β mandatory expression master regulator myogenic differentiation 1 proliferating myoblasts, thus controlling both commitment subsequent muscle-specific...
// Valentina Salizzato 1 , Christian Borgo Luca Cesaro Lorenzo A. Pinna Arianna Donella-Deana Department of Biomedical Sciences and CNR Institute NeuroSciences, University Padova, 35131 Italy Correspondence to: Donella-Deana, e-mail: arianna.donella@unipd.it Keywords: chronic myeloid leukaemia, imatinib-resistance, protein kinase CK2, rpS6, CX-5011 Received: November 03, 2015 Accepted: February 11, 2016 Published: 22, ABSTRACT Chronic leukaemia (CML) is a myeloproliferative disorder promoted...
Chronic myeloid leukemia (CML) is characterized by the fusion protein BCR::ABL1, a constitutively active tyrosine kinase. The frontline treatment, represented kinase inhibitors (TKIs), has dramatically improved clinical outcomes of patients. However, TKI resistance through various mechanisms been reported. In particular, BCR::ABL11 T315I mutation associated with to first- and second-generation TKIs poor survival outcomes. For patients harboring this mutation, treatments third generation are...
2549 Background: ICIs lead to durable response and a significant survival improvement in limited number of advanced stage Mel NSCLC pts. The identification predictive circulating biomarkers could be promising tool optimize pts’ selection outcome for treatment. Methods: This is prospective real-world study enrolling pts referred four Italian Centers treated with ICIs. primary endpoint verify the presence an association between cytokines (IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNFα,...